Press Release: Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Dow Jones11-13

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") $(TVRD)$, a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its nancial and operating results for the third quarter ended September 30, 2026, and provided a business update.

Business and Clinical Program Updates:

TTI-109 -- Ulcerative Colitis (UC)

   -- Advancing development plans for TTI-109 in UC. Building on positive Phase 
      1 healthy volunteer results reported in July and the subsequent selection 
      of UC as its initial target indication, Tvardi is preparing to advance 
      TTI-109 into clinical development in UC, subject to clearance of our 
      Investigational New Drug (IND) application and additional funding. 
 
          -- The Phase 1 results confirmed the prodrug design, with TTI-109 
             delivering TTI-101-equivalent exposure with improved tolerability 
             and, across the active dose range, demonstrated reductions in 
             cellular and humoral immune populations known to correlate with UC 
             disease severity, providing pharmacodynamic evidence of STAT3 
             target engagement. 
 
   -- Published additional preclinical data supporting STAT3 inhibition in UC. 
      New findings published in the International Journal of Molecular Sciences 
      demonstrated that, in a preclinical model of chronic colitis, TTI-101 
      achieved colon tissue exposure approximately eightfold higher than in 
      plasma, normalized disease-associated changes in colon gene expression, 
      muted colitis-associated changes in the gut microbiome and prevented the 
      formation of colon adenocarcinomas, a long-term consequence of chronic 
      colitis. 
 
          -- The preclinical data highlights the potential of STAT3 inhibition 
             to address immune dysregulation, inflammation and fibrosis that 
             drive UC progression. These findings build on prior preclinical 
             studies in which TTI-101 and TTI-109 significantly reduced disease 
             activity across three acute colitis models representing distinct 
             immune axes. 

TTI-101 -- Hepatocellular Carcinoma $(HCC)$

   -- Advancing Phase 1b/2 REVERT LIVER CANCER study toward topline readout in 
      early first quarter of 2027. The ongoing REVERT LIVER CANCER study is 
      evaluating TTI-101 as monotherapy and in combination with established 
      therapies in patients with HCC. The Company expects to report topline 
      data early in the first quarter of 2027 to allow for complete cohort 
      evaluation. 

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, "We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps."

Key Upcoming Milestones

   -- 2027: Initiation of clinical trial of TTI-109 in UC, subject to IND 
      clearance and additional funding 
 
   -- Early first quarter of 2027: TTI-101 Phase 1b/2 HCC topline data 

Third Quarter 2026 Financial Results

Research and development expenses for the three months ended September 30, 2026, were $4.5 million, compared to $3.6 million for the comparable period in 2025. The increase was primarily driven by higher clinical costs associated with TTI-101.

General and administrative expenses were $1.9 million for the three months ended September 30, 2026, compared to $2.3 million for the three months ended September 30, 2025. The decrease was primarily driven by lower professional fees.

Net loss for the three months ended September 30, 2026, was $6.1 million, compared to a net loss of $5.5 million for the three months ended September 30, 2025.

Basic and diluted net loss per share attributable to common stockholders for the three months ended September 30, 2026, were both $(0.48), compared to basic and diluted net loss per share of $(0.59) for the three months ended September 30, 2025.

Cash and cash equivalents as of September 30, 2026, were $22.3 million, compared to cash, cash equivalents and short-term investments of $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash and cash equivalents will be sufficient to fund operations, as currently planned, into the third quarter of 2027. Advancing TTI-109 into UC and additional indications remain subject to additional funding and IND clearance.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in ulcerative colitis pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Cautionary Statement Regarding Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated bene ts of Tvardi's product candidates; its ongoing clinical trials and anticipated timing of reporting data from such trials; potential indications for its product candidates; its anticipated cash runway; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi's product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in UC on the timelines expected or at all; the ability to replicate results for preclinical studies and early clinical trials in later trials; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the signi cant net losses Tvardi has incurred since inception; Tvardi's ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi's clinical trials; the outcome of preclinical testing and clinical trials of Tvardi's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential bene ts and market acceptance of Tvardi's product candidates; Tvardi's anticipated cash runway; Tvardi's ability to attract, hire, and retain skilled executive officers and employees; Tvardi's ability to protect its intellectual property and proprietary technologies; Tvardi's reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi's lings with the Securities and Exchange Commission, including the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi's other documents subsequently led with or furnished to the SEC, all of which are available on the SEC's website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to re ect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

For Tvardi:

Tvardi Investor Relations

ir@tvardi.com

PJ Kelleher

LifeSci Advisors

617-430-7579

pkelleher@lifesciadvisors.com

 
                          TVARDI THERAPEUTICS 
                       Consolidated Balance Sheets 
           (Unaudited, amounts in thousands, except share and 
                           per share amounts) 
                            As of September 30,     As of December 31, 
                           ---------------------  ---------------------- 
                                   2026                    2025 
                           ---------------------  ---------------------- 
Assets 
    Current assets: 
     Cash and cash 
      equivalents           $            22,275    $           20,734 
    Short-term 
     investments                             --                10,077 
      Prepaid expenses 
       and other current 
       assets                               855                   727 
                               ----------------       --------------- 
Total current assets                     23,130                31,538 
Property and equipment, 
 net                                         28                    52 
Intangible assets, net                      275                   322 
Operating lease 
 right-of-use assets                         83                   144 
Other non-current assets                     17                    17 
                               ----------------       --------------- 
      Total assets          $            23,533    $           32,073 
                               ================       =============== 
 
Liabilities and 
Stockholders' Equity 
Current liabilities: 
    Accounts payable        $             2,076    $            3,219 
    Accrued expenses                      5,885                 7,707 
    Operating lease 
     liabilities, current 
     portion                                116                   116 
                               ----------------       --------------- 
      Total current 
       liabilities                        8,077                11,042 
Operating lease 
 liabilities, net of 
 current portion                             --                    85 
                               ----------------       --------------- 
      Total liabilities                   8,077                11,127 
 
Stockholders' Equity: 
    Common stock, $0.001 
     par value; 
     150,000,000 shares 
     authorized as of 
     September 30, 2026 
     and December 31, 
     2025; 13,345,956 
     shares and 9,381,344 
     shares issued and 
     outstanding as of 
     September 30, 2026 
     and December 31, 
     2025, respectively                      13                     9 
    Additional paid-in 
     capital                            145,278               131,379 
    Accumulated other 
     comprehensive 
     income                                  --                     8 
    Accumulated deficit                (129,835)             (110,450) 
                               ----------------       --------------- 
      Total stockholders' 
       equity                            15,456                20,946 
                               ----------------       --------------- 
      Total liabilities 
       and stockholders' 
       equity               $            23,533    $           32,073 
                               ================       =============== 
 
 
                           TVARDI THERAPEUTICS 
                   Consolidated Statements of Operations 
            (Unaudited, amounts in thousands, except share and 
                            per share amounts) 
                      For the Three Months      For the Nine Months Ended 
                       Ended September 30,            September 30, 
                    -------------------------  --------------------------- 
                        2026         2025          2026          2025 
                    ------------  -----------  ------------  ------------- 
Operating 
expenses: 
  Research and 
   development      $     4,474   $    3,603   $    13,387   $   12,520 
  General and 
   administrative         1,854        2,335         6,621        6,641 
                     ----------    ---------    ----------    --------- 
    Total 
     operating 
     expenses             6,328        5,938        20,008       19,161 
                     ----------    ---------    ----------    --------- 
Loss from 
 operations              (6,328)      (5,938)      (20,008)     (19,161) 
Interest income             204          411           623        1,063 
Other income, net            --           --            --        7,159 
                     ----------    ---------    ----------    --------- 
Net loss            $    (6,124)  $   (5,527)  $   (19,385)  $  (10,939) 
                     ==========    =========    ==========    ========= 
 
Net loss per 
share 
attributable to 
common 
stockholders: 
Basic               $     (0.48)  $    (0.59)  $     (1.85)  $    (1.62) 
                     ==========    =========    ==========    ========= 
Diluted             $     (0.48)  $    (0.59)  $     (1.85)  $    (2.50) 
                     ==========    =========    ==========    ========= 
Weighted-average 
common shares 
outstanding: 
Basic                12,653,836    9,377,079    10,484,162    6,757,955 
                     ==========    =========    ==========    ========= 
Diluted              12,653,836    9,377,079    10,484,162    7,244,785 
                     ==========    =========    ==========    ========= 
 
Comprehensive 
loss: 
  Net loss          $    (6,124)  $   (5,527)  $   (19,385)  $  (10,939) 
  Unrealized 
   (loss) gain on 
   short-term 
   investments               --           20            (8)           7 
                     ----------    ---------    ----------    --------- 
Comprehensive loss  $    (6,124)  $   (5,507)  $   (19,393)  $  (10,932) 
                     ==========    =========    ==========    ========= 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment